---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-017671"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-04-11T23:59:59+00:00"
generated_at: "2026-06-17T03:55:13.264115+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics secures up to $10M equity line from Lincoln Park Capital

## Summary
- Lincoln Park committed to buy up to $10M of common stock over 24 months at Company's discretion.
- Company issued 73,659 shares as commitment fee; purchases subject to volume and price limits.
- No upper limit on purchase price per share; Lincoln Park cannot short or hedge during term.
- Sales limited to 19.99% of outstanding shares unless stock price exceeds $3.6094 or shareholder approval obtained.
- Company may terminate agreement with one business day notice; no penalties or liquidated damages.

## SEC filing metadata
- accession: 0001140361-23-017671
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/0001140361-23-017671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/brhc10050812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-017671
- JSON: https://secwatch.observer/filing/0001140361-23-017671.json
- Plain text: https://secwatch.observer/filing/0001140361-23-017671.txt

## Key facts
- Material Agreements
  Ernexa Therapeutics Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2023-04-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Value: up to $10.0 million
  - Effective: 2023-04-05
  source text: On April 5, 2023, Eterna Therapeutics Inc., a Delaware corporation (the " Company "), entered into a purchase agreement (the " Purchase Agreement ") and a registration rights agreement (the " Registration Rights Agreement ") with Lincoln Park Capital Fund, LLC (" Lincoln Park "), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123017671/0001140361-23-017671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.